Background: The nuclear factor-ĸB (NF-ĸB) pathway activates many of the target genes that are critical to the initiation and establishment of endometriosis. We sought to examine the potential application of pyrrolidine dithiocarbamate (PDTC), a potent NF-ĸB inhibitor, in the treatment of endometriosis. Methods: The phosphorylation of IĸB, expression of nuclear p65 protein and NF-ĸB DNA binding in endometriotic epithelial cells (EECs), endometriotic eutopic epithelial cells (EuECs) and normal epithelial cells (NECs) were detected by Western blot analysis and electrophoretic mobility shift assay. Cyclooxgenase-2 (COX-2) gene and protein expressions in EECs were measured by RT-PCR and Western blot analysis. Prostaglandin E2 (PGE2) production of EECs was measured by ELISA. Results: PDTC in the absence or presence of tumor necrosing factor-α (TNF-α) showed stronger inhibitory effects on IĸB phosphorylation, expression of nuclear p65 protein and NF-ĸB DNA-binding activity in EECs than in EuECs or NECs. Pretreatment of EECs with PDTC resulted in a dose-dependent reduction in the TNF-α-induced expressions of COX-2 at gene and protein levels, as well as a reduction of PGE2 synthesis. Conclusion: PDTC may represent a novel therapeutic strategy for treatment of endometriosis.

Keywords:
Pyrrolidine dithiocarbamate, Nuclear factor-ĸB, Endometriosis, Cyclooxgenase-2, Prostaglandin E2
1.
Ebert AD, Bartley J, David M: Aromatase inhibitors and cyclooxygenase-2 inhibitors in endometriosis: new questions – old answers? Eur J Obstet Gynecol Reprod Biol 2005;122:144–150.
2.
Ota H, Igarashi S, Sasaki M, Tanaka T: Distribution of cyclooxygenase-2 in eutopic and ectopic endometrium in endometriosis and adenomyosis. Hum Reprod 2001;16:561–566.
3.
Olivares C, Bilotas M, Buquet R, Borghi M, Sueldo C, Tesone M, Meresman G: Effects of a selective cyclooxygenase-2 inhibitor on endometrial epithelial cells from patients with endometriosis. Hum Reprod 2008;23:2701–2708.
4.
Attar E, Bulun SE: Aromatase and other steroidogenic genes in endometriosis: translational aspects. Hum Reprod Update 2006;12:49–56.
5.
Wu Y, Guo SW: Suppression of IL-1β-induced COX-2 expression by trichostatin A) in human endometrial stromal cells. Eur J Obstet Gynecol Reprod Biol 2007;135:88–93.
6.
Morais C, Pat B, Gobe G, Johnson DW, Healy H: Pyrrolidine dithiocarbamate exerts anti-proliferative and pro-apoptotic effects in renal cell carcinoma cell lines. Nephrol Dial Transplant 2006;21:3377–3388.
7.
Iba Y, Harada T, Horie S, Deura I, Iwabe T, Terakawa N: Lipopolysaccharide-promoted proliferation of endometriotic stromal cells via induction of tumor necrosis factor-α and interleukin-8 expression. Fertil Steril 2004;82(suppl 3):1036–1042.
8.
Sakamoto Y, Harada T, Horie S, Iba Y, Taniguchi F, Yoshida S, Iwabe T, Terakawa N: Tumor necrosis factor-α-induced interleukin-8 (IL-8) expression in endometriotic stromal cells, probably through nuclear factor-ĸB activation: gonadotropin-releasing hormone agonist treatment reduced IL-8 expression. J Clin Endocrinol Metab 2003;88:730–735.
9.
Wieser F, Vigne JL, Ryan I, Hornung D, Djalali S, Taylor RN: Sulindac suppresses nuclear factor-ĸB activation and RANTES gene and protein expression in endometrial stromal cells from women with endometriosis. J Clin Endocrinol Metab 2005;90:6441–6447.
10.
Nasu K, Nishida M, Ueda T, Yuge A, Takai N, Narahara H: Application of the selective nuclear factor-ĸB inhibitor, BAY 11-7085, for the treatment of endometriosis: an in vitro study. Am J Physiol Endocrinol Metab 2007;293:E16–E23.
11.
Wang F, He YL, Peng DX, Liu MB: Expressions of nuclear factor-ĸB and intercellular adhesion molecule-1 in endometriosis. Di Yi Jun Yi Da Xue Xue Bao 2005;25:703–705.
12.
Grund EM, Kagan D, Tran CA, Zeitvogel A, Starzinski-Powitz A, Nataraja S, Palmer SS: Tumor necrosis factor-α regulates inflammatory and mesenchymal responses via mitogen-activated protein kinase kinase, p38, and nuclear factor-ĸB in human endometriotic epithelial cells. Mol Pharmacol 2008;73:1394–1404.
13.
Celik O, Hascalik S, Elter K, Tagluk ME, Gurates B, Aydin NE: Combating endometriosis by blocking proteasome and nuclear factor-ĸB pathways. Hum Reprod 2008;23:2458–2465.
14.
Bulun SE, Lin Z, Imir G, Amin S, Demura M, Yilmaz B, Martin R, Utsunomiya H, Thung S, Gurates B, Tamura M, Langoi D, Deb S: Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol Rev 2005;57:359–383.
15.
Buchweitz O, Poel T, Diedrich K, Malik E: The diagnostic dilemma of minimal and mild endometriosis under routine conditions. J Am Assoc Gynecol Laparosc 2005;10:85–89.
16.
Laschke MW, Elitzsch A, Scheuer C, Vollmar B, Menger MD: Selective cyclooxygenase-2 inhibition induces regression of autologous endometrial grafts by down-regulation of vascular endothelial growth factor-mediated angiogenesis and stimulation of caspase-3-dependent apoptosis. Fertil Steril 2007;87:163–171.
17.
Banu SK, Lee J, Speights VO Jr, Starzinski-Powitz A, Arosh JA: Cyclooxygenase-2 regulates survival, migration, and invasion of human endometriotic cells through multiple mechanisms. Endocrinology 2008;149:1180–1189.
18.
Wu MH, Sun HS, Lin CC, Hsiao KY, Chuang PC, Pan HA, Tsai SJ: Distinct mechanisms regulate cyclooxygenase-1 and -2 in peritoneal macrophages of women with and without endometriosis. Mol Hum Reprod 2002;8:1103–1110.
19.
Gately S, Li WW: Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol 2004;31(suppl 7):2–11.
20.
Colette S, Lousse JC, Defrère S, Curaba M, Heilier JF, Van Langendonckt A, Mestdagt M, Foidart JM, Loumaye E, Donnez J: Absence of aromatase protein and mRNA expression in endometriosis. Hum Reprod 2009;24:2133–2141.
21.
Hellmuth M, Wetzler C, Nold M, Chang JH, Frank S, Pfeilschifter J, Mühl H: Expression of interleukin-8, heme oxygenase-1 and vascular endothelial growth factor in DLD-1 colon carcinoma cells exposed to pyrrolidine dithiocarbamate. Carcinogenesis 2002;23:1273–1279.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.